Recursion Pharmaceuticals, Inc.
RXRX
$4.94
$0.163.35%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.22M | 14.75M | 4.55M | 26.08M | 14.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.22M | 14.75M | 4.55M | 26.08M | 14.42M |
| Cost of Revenue | 148.80M | 151.46M | 111.13M | 86.68M | 83.13M |
| Gross Profit | -129.57M | -136.72M | -106.58M | -60.60M | -68.71M |
| SG&A Expenses | 46.65M | 54.65M | 77.29M | 37.76M | 31.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 195.45M | 206.11M | 188.42M | 124.44M | 114.96M |
| Operating Income | -176.23M | -191.37M | -183.88M | -98.35M | -100.54M |
| Income Before Tax | -171.90M | -202.65M | -178.90M | -95.68M | -98.06M |
| Income Tax Expenses | -- | -158.00K | 7.00K | 167.00K | -523.00K |
| Earnings from Continuing Operations | -171.90M | -202.49M | -178.91M | -95.84M | -97.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -171.90M | -202.49M | -178.91M | -95.84M | -97.54M |
| EBIT | -176.23M | -191.37M | -183.88M | -98.35M | -100.54M |
| EBITDA | -152.38M | -172.04M | -170.93M | -91.16M | -91.58M |
| EPS Basic | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 |
| Normalized Basic EPS | -0.26 | -0.31 | -0.33 | -0.21 | -0.25 |
| EPS Diluted | -0.41 | -0.50 | -0.54 | -0.34 | -0.40 |
| Normalized Diluted EPS | -0.26 | -0.31 | -0.33 | -0.21 | -0.25 |
| Average Basic Shares Outstanding | 417.36M | 402.77M | 336.04M | 282.58M | 242.20M |
| Average Diluted Shares Outstanding | 417.36M | 402.77M | 336.04M | 282.58M | 242.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |